Cargando…

NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer

OBJECTIVE: Treatment efficacy of androgen deprivation therapy with radical prostatectomy for intermediate- to high-risk prostate cancer is less well-studied. The NEAR trial is a single-arm, phase II investigation of neoadjuvant apalutamide monotherapy and radical prostatectomy (RP) in the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Lui Shiong, Sim, Adelene Y. L., Ong, Chee Wee, Yang, Xinyan, Ng, Cedric C. Y., Liu, Wei, Rajasegaran, Vikneswari, Lim, Abner M. S., Aslim, Edwin Jonathan, Ngo, Nye-Thane, Khor, Li-Yan, Kanesvaran, Ravindran, Allen, John Carson Jr, Tay, Kae Jack, Yuen, John Shyi Peng, Chong, Tsung Wen, Ho, Sun Sien Henry, Teh, Bin Tean, Chua, Melvin L. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705244/ https://www.ncbi.nlm.nih.gov/pubmed/35091711 http://dx.doi.org/10.1038/s41391-022-00496-8

Ejemplares similares

Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer
por: Lee, Lui Shiong, et al.
Publicado: (2022)

Defining prostate cancer size and treatment margin for focal therapy: does intralesional heterogeneity impact the performance of multiparametric MRI?
por: Aslim, Edwin Jonathan, et al.
Publicado: (2021)

The optimal management of variant histology in muscle invasive bladder cancer
por: Tiwari, Raj Vikesh, et al.
Publicado: (2020)

Hypothyroidism caused by apalutamide
por: Daviduck, Quinn, et al.
Publicado: (2023)

Multiparametric MRI reporting using Prostate Imaging Reporting and Data System version 2.0 (PI-RADSv2) retains clinical efficacy in a predominantly post-biopsy patient population
por: Aslim, Edwin Jonathan, et al.
Publicado: (2019)

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
por: Koshkin, Vadim S., et al.
Publicado: (2018)

Clinicopathological features of non-conventional renal cell carcinoma histological subtypes: Learning points from a large contemporary series spanning over three decades
por: Lim, Ee Jean, et al.
Publicado: (2022)

Bizarre giant cells in human angiosarcoma exhibit chemoresistance and contribute to poor survival outcomes
por: Tan, Grace Fangmin, et al.
Publicado: (2020)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Psoriatic Skin Lesions after Apalutamide Treatment
por: MIYAGAWA, Fumi, et al.
Publicado: (2022)

Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract Cancers
por: Lim, Abner Herbert, et al.
Publicado: (2022)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Sequencing and comparative analysis of fugu protocadherin clusters reveal diversity of protocadherin genes among teleosts
por: Yu, Wei-Ping, et al.
Publicado: (2007)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial
por: Chung, Byung Ha, et al.
Publicado: (2021)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
por: Alkhudair, Nora A.
Publicado: (2019)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race‐specific luminal‐basal and microenvironmental differences
por: Chua, Melvin L. K., et al.
Publicado: (2023)

Surveillance one year post focal cryotherapy for clinically significant prostate cancer using mpMRI and PIRADS v2.1: An initial experience from a prospective phase II mandatory biopsy study
por: Velaga, Jyothirmayi, et al.
Publicado: (2023)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

A comprehensive next generation sequencing tissue assay for Asian-prevalent cancers—Analytical validation and performance evaluation with clinical samples
por: Ng, Cedric Chuan-Young, et al.
Publicado: (2022)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Pharmacokinetics and Use‐Testing of Apalutamide Prepared in Aqueous Food Vehicles for Alternative Administration
por: Yu, Alex, et al.
Publicado: (2021)

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
por: Brown, Gordon, et al.
Publicado: (2022)

Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer
por: Eberli, Daniel, et al.
Publicado: (2022)

(68)Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
por: Tan, Janice S.H., et al.
Publicado: (2019)

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer
por: De Velasco, Marco A., et al.
Publicado: (2021)

Apalutamide‐associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy
por: Tohi, Yoichiro, et al.
Publicado: (2021)

Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer
por: Honda, Tomoko, et al.
Publicado: (2022)

Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial
por: Miyake, Hideaki, et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
por: Tombal, B., et al.
Publicado: (2022)

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
por: Tosco, Lorenzo, et al.
Publicado: (2018)

Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Caused by Apalutamide: A Case Presentation
por: Martin, Gabriella, et al.
Publicado: (2023)

Whole‐exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1
por: McPherson, John Richard, et al.
Publicado: (2015)

Targeted therapy for renal cell carcinoma: The next lap
por: Kanesvaran, Ravindran, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9pid04qj0osh60gv595kvrge31